Welcome to our dedicated page for Cronos Group SEC filings (Ticker: CRON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for Cronos Group Inc. (CRON), a cannabinoid-focused company listed on NASDAQ and the Toronto Stock Exchange. As a foreign private issuer incorporated in British Columbia, Canada, Cronos files reports with the SEC under Commission File Number 001-38403, giving investors structured insight into its operations, governance and financial condition.
Cronos’ SEC disclosure includes current reports on Form 8-K, which the company uses to announce material events. Recent 8-K filings have covered quarterly financial results, such as press releases for the second and third quarters of 2025, and corporate governance matters, including the appointment and subsequent termination of the company’s principal accounting officer and the results of the 2025 Annual Meeting of Shareholders. These filings provide detail on topics like voting outcomes for director elections, advisory votes on executive compensation and the appointment of the independent auditor.
Through this filings page, users can also review Cronos’ periodic reports (such as annual and quarterly filings referenced in its 8-Ks) to understand trends in revenue, gross profit, adjusted EBITDA and other metrics the company discusses in its earnings materials. The filings describe elements of Cronos’ business, including its cannabis brands, international operations and investments such as its interest in Cronos Growing Company Inc. (Cronos GrowCo).
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly identify important changes in financial performance, governance or strategy. Real-time updates from the EDGAR system ensure that new Cronos 8-Ks, 10-K equivalents for foreign issuers, 10-Q equivalents and proxy materials are added as they are filed, while insider transaction reports on Form 4, if applicable, can be used to monitor share dealings by directors and officers.
By combining Cronos’ official SEC filings with AI-generated explanations, this page is designed to make the company’s regulatory disclosures more accessible to investors, analysts and other stakeholders.
Cronos Group Inc. officer Buggy Shannon reported compensation-related stock activity involving restricted stock units and common shares. On March 9, 2026, Shannon received a grant of 48,638 RSUs, each representing one common share, vesting in three equal annual installments starting one year after the grant date.
On March 8, 2026, Shannon exercised RSUs covering 21,148 and 25,378 underlying common shares. To satisfy tax obligations, the company withheld 10,526 and 12,918 common shares at $2.57 per share. Following these transactions, Shannon directly held 142,941 common shares and 243,774 RSUs.
Cronos Group Inc. officer Anna Shlimak reported several equity compensation transactions involving restricted stock units (RSUs) and common shares. On March 9, 2026, she received grants of 166,459 RSUs and 23,134 RSUs, each RSU representing one common share and vesting in three annual installments beginning on the first anniversary of the grant date.
On March 8, 2026, she exercised 45,680 RSUs into the same number of common shares, reflecting vesting from a prior grant dated March 8, 2024. Of those common shares, 18,943 were withheld at $2.57 per share to cover tax obligations, which is a non-market disposition. Following these transactions, she directly holds 280,923 common shares and 507,916 RSUs.
Cronos Group Inc. reported initial equity holdings for officer Jared Matthew Kenost. He holds 46,003 restricted stock units and 29,388 common shares, all directly owned. Each restricted stock unit represents a right to receive one Cronos common share in the future.
The 46,003 RSUs include 28,238 units vesting in three equal annual installments beginning on May 12, 2026, 10,230 units vesting in two equal annual installments beginning on May 10, 2026, and 7,535 units vesting on May 10, 2026, in each case subject to continued employment.
Cronos Group Inc. is a British Columbia–incorporated cannabinoid company with operations in Canada and Israel and common shares listed on Nasdaq and TSX under “CRON.” It focuses on building brands such as Spinach®, PEACE NATURALS®, LIT™ and Lord Jones® and expanding medical and adult-use distribution globally.
The company’s strategy centers on iconic brands, a diversified sales network, an efficient global supply chain and monetizing intellectual property, supported by joint ventures like Cronos Israel and Cronos GrowCo. Altria Group, Inc. beneficially owns 41.0% of Cronos and holds extensive board representation, approval, pre-emptive and top-up rights.
Cronos highlights significant risks, including ongoing losses and the challenge of achieving sustained profitability, heavy reliance on joint ventures and imports into Israel, exposure to the Middle East conflict and an anti-dumping investigation in Israel, complex and evolving cannabis regulations worldwide, intense competition (including illegal markets) and prior financial restatements, internal control weaknesses and settlements with U.S. and Canadian securities regulators.
Cronos Group Inc. reported strong growth for 2025 while staying roughly breakeven on the bottom line. Net revenue rose 25% to $146.6 million, with Q4 net revenue up 47% year-over-year to $44.5 million, driven by cannabis flower sales in Israel and other international markets plus higher Canadian flower and extract sales.
Full-year gross profit increased to $62.8 million, and gross margin expanded to 43%. Adjusted EBITDA swung to a positive $10.1 million from a loss of $34.9 million in 2024, reflecting higher adjusted gross profit and lower operating expenses. The company recorded a modest net loss of $2.9 million, compared with net income of $40.0 million a year earlier, mainly due to foreign currency transaction losses versus prior gains.
Cronos ended 2025 with an industry-leading liquidity position of $831.8 million in cash and cash equivalents plus short-term investments. It agreed to acquire Dutch producer CanAdelaar for upfront cash consideration of €57.5 million (approximately $67 million) plus an earnings-based earnout, gaining a leading supplier in the Netherlands’ legal adult-use cannabis experiment. The company highlighted strong brand momentum for Spinach®, SOURZ by Spinach®, PEACE NATURALS® and Lord Jones® across Canada and Israel, and appointed Jared Matthew Kenost as Principal Accounting Officer and Vice President, Controller.
Cronos Group Inc. reported insider equity transactions by Chairman, Chief Executive Officer and President Michael R. Gorenstein dated December 13, 2025. He acquired 166,642 common shares through the conversion of restricted stock units at a reported price of $0 and disposed of 65,002 common shares at $3.27 per share.
Following these transactions, he directly owns 12,610,412 common shares and holds 1,999,977 restricted stock units, each representing a contingent right to receive one Cronos common share. These units were originally granted on December 13, 2022 in an award of 499,826 restricted stock units vesting in three substantially equal annual installments beginning on the first anniversary of the grant date.
Cronos Group Inc. executive Arye Weigensberg, Senior Vice President and Head of Research and Development, reported the vesting and settlement of 6,423 restricted stock units into common shares on 12/13/2025 at an exercise price of $0 per share.
After this transaction, he directly owns 135,892 Cronos Group common shares and continues to hold 153,918 restricted stock units, each representing a contingent right to receive one common share. These RSUs were originally granted on December 13, 2022 as part of a 19,266-unit award vesting in three substantially equal annual installments.
Cronos Group Inc. (CRON) filed a Form 4 reporting an equity award to an executive. On November 7, 2025, the SVP, Head of Cronos Israel, received 60,728 restricted stock units (RSUs), each representing the right to receive one common share. The RSUs vest in three substantially equal annual installments beginning on the first anniversary of the grant date. Following this grant, 138,632 derivative securities were beneficially owned directly.
Cronos Group Inc. reported stronger Q3 results. For the three months ended September 30, 2025, net revenue was $36.3 million versus $34.3 million a year ago, led by cannabis flower $26.4 million and extracts $10.0 million. Gross profit rose to $18.3 million from $3.6 million as cost of sales declined.
Operating loss narrowed to $0.5 million from $33.7 million. Total other income was $27.5 million, including a foreign currency gain of $19.8 million and a $4.1 million gain on revaluation of financial instruments, partly offset by a $3.0 million loss on held-for-sale assets and a $4.8 million change in allowance for credit loss on a non-operating loan. Net income attributable to Cronos Group was $26.0 million ($0.07 per diluted share), up from $8.3 million ($0.02) in the prior-year quarter.
Cash and cash equivalents were $784.2 million with $40.0 million of short-term investments. Total assets were $1.178 billion against total liabilities of $46.4 million. Year-to-date, operating activities provided $14.0 million of cash, while investing used $79.3 million and financing used $12.5 million. Canada contributed $23.1 million of quarterly revenue and Israel $11.4 million. Shares outstanding were 382,893,267 as of November 3, 2025.
Cronos Group Inc. furnished an 8-K announcing it issued a press release with financial results for its third quarter ended September 30, 2025.
The press release is attached as Exhibit 99.1. The Item 2.02 information, including Exhibit 99.1, is being furnished, not filed, and is not subject to Section 18 liability or automatically incorporated into other filings. Exhibit 104 provides the cover page Inline XBRL data.